Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-Dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism.

Next Previous
Trial Profile

Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-Dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilostazol (Primary) ; Clopidogrel (Primary) ; Aspirin
  • Indications Myocardial infarction; Stent thrombosis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms ACCEL-AMI-CYP2C19

Most Recent Events

  • 28 Jul 2011 Results presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.
  • 21 Feb 2011 Primary endpoint 'Platelet-aggregation' has been met
  • 10 Nov 2009 Trial phase changed from III to IV as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top